J. Brevard

发表

Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials

M. Hellerstein, P. Schroeder, L. Morrow, 2020, Diabetes, obesity & metabolism.

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.

R. Arbeit, E. Prens, H. Thio, 2017, Clinical immunology.

Design Considerations for Clinical Trials Using the Cutaneous Dermatomyositis Disease Area and Severity Index as a Primary Endpoint

V. Werth, D. Fiorentino, J. Horobin, 2017 .

The histamine skin prick test: An analysis of the method for use in clinical trials.

M. Bednar, D. Volfson, A. Ogden, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

A. Wei, S. de Botton, Sangmin Lee, 2022, The Lancet. Haematology.

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

H. Colman, B. V. Van Tine, S. Guichard, 2022, Neuro-oncology.

Connecting to Young Adults: An Online Social Network Survey of Beliefs and Attitudes Associated With Prescription Opioid Misuse Among College Students

S. Budman, S. Lord, J. Brevard, 2011, Substance use & misuse.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

G. Garcia-Manero, R. Paquette, M. Grunwald, 2019, Blood.

PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

J. Cortes, G. Schiller, K. Seiter, 2019, HemaSphere.

D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects.

R. Kozak, Patrick E. Trapa, David L. Gray, 2020, ACS chemical neuroscience.

Teaching adolescents about changing bodies: Randomized controlled trial of an Internet puberty education and body dissatisfaction prevention program.

Tara M Cousineau, D. Franko, Meredith Trant, 2010, Body image.

Two-minute skin anesthesia through ultrasound pretreatment and iontophoretic delivery of a topical anesthetic: a feasibility study.

Nathaniel Katz, Egilius L H Spierings, J. Brevard, 2008, Pain medicine.

MyStudentBody–Stress: An Online Stress Management Intervention for College Students

Sarah Lord, Emil Chiauzzi, E. Chiauzzi, 2008, Journal of health communication.

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

J. Cortes, A. Khwaja, P. Fenaux, 2023, Blood advances.

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

A. Khwaja, P. Fenaux, A. Wei, 2022, Blood.

Abstract 5652: Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma

J. Wargo, R. Murthy, R. Amaria, 2017 .

MyStudentBody–Stress: An Online Stress Management Intervention for College Students

E. Chiauzzi, S. Lord, J. Brevard, 2008, Journal of health communication.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

J. Cortes, A. Wei, Sangmin Lee, 2019, Blood.

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

J. Cortes, A. Wei, Sangmin Lee, 2019, Blood.